Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Vanderbilt-Ingram Cancer Center General Information Contact Information Nonprofit Vanderbilt-Ingram Cancer Center Address 691 Preston Building Nashville, TN 37232 Phone (615) 936-5847 Fax 615 936-0236 Web Site Web Site Facebook Facebook Twitter Twitter Email [email protected] At A Glance Year of Incorporation 1993 1 Mission & Impact Statements Mission The mission of the Vanderbilt-Ingram Cancer Center is to alleviate cancer death and suffering through pioneering research; innovative patient-centered care; and evidence-based prevention, education and community initiatives. Background Vanderbilt University Medical Center has been at the forefront of groundbreaking cancer research and treatment for decades. This legacy began with the work of Nobel laureates Earl Sutherland and Stanley Cohen, whose research in cell communication, growth and dissemination are the foundation of many of today's breakthroughs in cancer treatment. Building on that history, the Vanderbilt Cancer Center was formally established in 1993 under the leadership of Dr. Hal Moses. The Center consolidated all cancer-related research, treatment, education and outreach at Vanderbilt with the immediate objective of joining the ranks of the premier institutions designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI). Two years later, Vanderbilt became the youngest center to go from creation to designation with its initial status as a "clinical cancer center." In 1999, Nashville's Ingram family made a transformational gift in honor of the late E. Bronson Ingram, philanthropist, businessman and civic leader. The center became known as the Vanderbilt-Ingram Cancer Center (VICC) in recognition of this important partnership. In 2001, the Center earned NCI's top distinction as a Comprehensive Cancer Center, and remains one of only a fraction of such centers in the United States. In 2008, Jennifer A. Pietenpol, Ph.D., Vanderbilt Professor of Biochemistry, Cancer Biology and Otolaryngology, was named Director of the VICC. Later that year, President Obama appointed her to serve a six-year term on the NCI’s National Cancer Advisory Board. In 2007, the Center was invited to join the prestigious National Comprehensive Cancer Network, a non-profit alliance of the nation’s top centers. These centers are recognized as being at the forefront of cancer diagnosis, treatment, and support care and leading the way at conducting ground-breaking research. In July 2010, the VICC launched the Personalized Cancer Medicine Initiative, becoming the first cancer center in the Southeast to offer cancer patients routine genotyping of their tumors at the DNA level. The Center continues to be a national leader in precision medicine. In 2015, the Center successfully renewed its Comprehensive Cancer Center designation and was recognized by its peers and the NCI as one of the very best Centers in the country. 2 Impact The Vanderbilt-Ingram Cancer Center (VICC) is a national leader in patient care and research. One of the top cancer centers in the nation; in 2015 the National Cancer Institute renewed VICC’s designation as a Comprehensive Cancer Center – the only one in Tennessee that cares for adults as well as children. U.S. News and World Report consistently lists Vanderbilt as one of the Best Cancer Hospitals in the nation. Patients treated at VICC and their affiliated hospitals have access to top specialists in all types of cancer, from the more common to the rare and to innovative therapies through clinical trials that may not be available at community hospitals. Members of the VICC are highly talented, creative, and regarded investigators in the cancer research community. These investigators bring in over $130M annually in extramural grant funding, publish cancer discoveries in the top journals, educate and mentor the next generation of physicians and researchers, hold leadership roles in many national organizations, and are recognized nationally with awards and honors by their peers. In addition, Vanderbilt-Ingram has been consistently recognized by the NCI as a Specialized Program of Research Excellence in both GI and Breast Cancer. In the past several years, the VICC has become one of the lead academic institutions to implement tumor genotyping to identify “actionable” tumor mutations in patients, and, importantly, to integrate this genotyping into clinical care decision-making. At VICC, tumor genotyping information is integrated into the patients’ medical record with an informatics tool, My Cancer Genome (MCG), to help physicians understand the clinical significance of genotyping results. Developed by VICC investigators, MCG (mycancergenome.org) provides information about the detected mutation(s), discusses the therapies for tumors with respective genotypes and lists clinical trials available at VICC and worldwide for particular diseases. VICC investigators are studying the biological mechanisms that lead to treatment resistance in melanoma. V600 Approximately half of all melanoma patients have tumors that harbor a BRAF gene mutation. Therapies that target BRAF are usually effective, but within a few months nearly all patients develop resistance to the therapy and their cancer progresses. Investigators at the VICC found a variety of genetic mutations that lead to this acquired resistance. This study provides insights into strategies to address treatment resistance. For the first time, VICC investigators used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy is being tested in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). VICC is the first cancer center in Tennessee to treat a patient with the new investigational technology. Investigators at the VICC continue a landmark investigation tracking the cancer and other disease experience of a cohort of nearly 86,000 adults in the southeastern United States. The Southern Community Cohort Study (SCCS), by design, has among the highest representation of African Americans compared to other cohort studies, and is poised to address scientific questions about the causes of both common and rare cancers in underrepresented minority populations, as well as the health disparities that exist in these populations. In the coming years, the VICC will continue to support innovative cancer research and expand upon select areas of research for continued translation of discoveries to the patient. There will be a major emphasis on focused expansion of research areas through recruitment of talented investigators that can further integrate basic research with clinical, epidemiological and population-based research initiatives. There will be continued focus on cancer drug discovery and imaging, expansion of hematologic malignancies and agile development of informatics tools to support research, clinical genomics and point-of-care decision-making. In doing so, we will further strengthen the position of VICC, a matrix cancer center, within the university, region and nation as a top provided of quality cancer care. 3 Needs According to the National Cancer Institute, approximately 39.6 percent of men and women will be diagnosed with cancer at some point during their lifetimes. Virtually no one is left untouched by the impact of this disease. A cancer diagnosis is life-altering for both the patient and their family. Giving to the Vanderbilt-Ingram Cancer Center (VICC) helps us continue to make a difference in the lives of countless individuals facing a cancer diagnosis. Through generous gifts made by donors, the VICC is able to accelerate the development of diagnostic tests and novel treatment options; recruit talented physicians and scientists in all fields of cancer research and care; enhance existing and develop new prevention programs that reach a broad population; develop programs to support cancer survivors and their families; and provide patients with access to state-of-the-art facilities, enhancing the approach to cancer care and delivery. VICC is driven to excel and continue to lead in the translation of new discoveries from bench to bedside and back to the bench. Gifts large and small keep VICC on the leading edge of world-class health care and discovery. Giving to the Vanderbilt-Ingram Cancer Center (VICC) helps us continue to make a difference in the lives of countless individuals facing a cancer diagnosis. Through generous gifts made by donors, the VICC is able to accelerate the development of diagnostic tests and novel treatment options; recruit top physicians and scientists in all fields of cancer care and research; enhance existing and develop new prevention programs that reach a broad population; develop programs to support cancer survivors and their families; and provide patients with access to state-of-the-art facilities, enhancing the approach to cancer care and delivery. Gifts large and small keep VICC on the leading edge of world-class health care and discovery. Other ways to donate, support, or volunteer Cancer and its impact on the patient and loved ones are too daunting a health challenge to be conquered easily or without a true team effort. You can be a part of that team - and part of conquering cancer - by making a charitable contribution to support cancer research or patient support. Your gift can make a huge difference in the lives of cancer patients and their families, today and in the future. • To make a gift • To request information about other gifts, including cash, securities, memorial, tribute, gift annuity, charitable remainder trust or other gifts, please call Vanderbilt-Ingram’s Development Office at 615-936-0233 or 800288-0028 or email us at [email protected]. • Contributions may also be mailed to: Vanderbilt-Ingram Cancer Center c/o Gifts Processing PMB 407727 2301 Vanderbilt Place Nashville, TN 37240-7727 • Find out more about Donor Supported Research • Find out how to Volunteer Service Categories Primary Organization Category Health Care / Speciality Hospitals Secondary Organization Category Medical Research / Cancer Research Tertiary Organization Category Diseases Disorders & Medical Disciplines / Cancer Areas of Service Areas Served 4 KY TN National We treat patients largely from the Southeast region of the United States. We are also the cancer center of choice for patients from around the country seeking treatment for specific cancers, particularly those that are rare or aggressive. CEO Statement A personal experience is often the catalyst for private gifts of millions that will allow cancer scientists to do everything from prove the value of an untested idea to harvest tissue samples that will be used for years in research studies. Some donors attach very specific uses to their dollars. But others – the Ingram Foundation as an example – give with the only restriction that the cancer center put the funds where they will have the biggest impact. Vanderbilt-Ingram uses outside peer review to help prioritize projects based on scientific merit. Unlike governmental funding, private money is often used to seed and nurture early ideas that are considered a bit riskier to support. Private money accelerates discoveries jump-starts the contributions of exceptional, earlycareer scientists. Private funds also support the less glamorous but absolutely essential tasks of the research process, such as collecting and storing tissue and blood samples. We believe these biological storehouses hold the key that will unlock the individualization of cancer diagnosis and treatment in years to come. Vanderbilt-Ingram can begin to dissect genetic and molecular patterns that are predictive of cancer, an effort that has gained impetus from the quick turnaround capabilities of today’s advanced technologies. Using funds to find the roots of cancer will put us in a strong position to develop simple screening tests. The sequencing of the human genome and other recent scientific advances has made this a truly promising era of medical research. But the technology and talent needed to fulfill that promise are expensive. As the funds from the NIH become scarcer in the face of a flat-if-not-decreasing budget, the role of philanthropy becomes even more critical to keeping the science moving forward and capitalizing on the investment made in recent years. We have the opportunity to make medical breakthroughs. It is all determined by how much money we have to perform the work. 5 Programs Programs Director's Fund Description Cancer science is on the brink of unparalleled breakthroughs, and the Vanderbilt-Ingram Cancer Center is uniquely positioned to help change the course of this devastating disease. Funding for novel research, however, is threatened if we must rely on traditional sources for support. The majority of cancer research is funded by the National Cancer Institute (NCI). Grants from the NCI are awarded to doctors and scientists based upon the scientific merit of projects and substantiating research data. Our Director's Fund gives VICC researchers the opportunity to test novel approaches and acquire the necessary data needed for a successful proposal. Funding supports promising projects with a goal of translating new discoveries. The VICC has an impressive track record of new projects started by private donations that have gone on to secure substantial funding and produce important, groundbreaking discoveries in colon, breast and lung cancer. Population Served ,, Discovery Grants Description Discovery Grants provide crucial funding to accelerate bold, innovative research ideas. Whether contributing $50 or $50K, donors can support the early stages of major new research initiatives, enabling these researchers and scientists to obtain important data giving direction to future research. Historically, discovery grants provide a significant return on investment, in that they directly contribute to researchers securing substantive future grant funds. The Vanderbilt-Ingram Cancer Center (VICC) Ambassadors, a dynamic group that fundraises for discovery grants to promising researchers at VICC, has awarded approximately $630,000 since 2009. In those five years, that investment in new research initiatives has enabled recipients to secure nearly $12M in follow-on funding from leading research institutions such as the National Cancer Institute, National Institutes of Health, and the Department of Defense. Population Served ,, 6 Patient and Family Education and Support Resources Description The Vanderbilt-Ingram Cancer Center (VICC) strives to treat the physical, emotional and practical needs of cancer patients and their caregivers through educational and support programs. The Patient and Family Resource Center is a one-stop information resource for cancer-related issues for anyone who has been touched by cancer. It includes free brochures, pamphlets and access to web-based information. Each newly diagnosed cancer patient treated at VICC receives an educational, individually-tailored notebook including information about cancer care, resources and support. The Vanderbilt Cancer Wellness Program promotes the health and wellbeing of those touched by cancer through interactive, individualized, and comprehensive programs. Examples of programs include: gentle movement classes; survivorship clinic; hereditary risk clinic; fitness consults; lymphedema therapy; acupuncture; massage therapy; yoga; smoking cessation and nutritional counseling. Population Served ,, Precision Medicine Description Vanderbilt-Ingram Cancer Center (VICC) is focused on delivering precision cancer medicine to its patients. Precision medicine is when the molecular variants of a patient’s individual tumor, such as gene mutations, are used to determine the best course of treatment—to its patients. In 2011, VICC launched My Cancer Genome, a website that serves this goal by enabling cancer patients, their doctors, and cancer researchers to quickly access up-to-date information about how cancer-related molecular variants can affect the course of cancer treatment. Each week, My Cancer Genome provides information on cancer mutations, therapies, clinical trials, and precision medicine to more than 9,000 people around the world—less than half of whom are in the United States. When My Cancer Genome began in 2010, it covered only a few genes and mutations in two cancer types. It now covers more than 300 variants, 820 genes, 22 cancer types, and 550 drugs for a total of about 1,500 pages. My Cancer Genome is once again in the process of transforming the way it generates and maintains content, so that it can provide more content, more quickly, so that patients can get the information they need to make the best treatment decisions sooner. Population Served ,, 7 Survivorship Description Surviving cancer is a milestone accomplishment. Thanks to innovative research and improved treatments, there are almost 13 million cancer survivors alive today. By 2020, it is expected that there will be two million new cancer survivors every year in the United States. The rise in survival rates to almost 80 percent for children and 65 percent for adults has created a new challenge for health care providers today: providing appropriate comprehensive follow-up care for the increasing numbers of cancer survivors. Cancer survivors often face physical, emotional, social, and financial challenges as a result of their diagnosis and treatment. Vanderbilt’s REACH (Research, Education, Advocacy, Care, Health) Survivorship Program focuses on improving health outcomes in children and adults living with, through, and after cancer. The overall goal is to decrease the burden of cancer by developing a well-integrated program of education, advocacy, clinical care, and interdisciplinary research, thus creating a positive community of survivors and their families. Vanderbilt’s REACH Survivorship Program serves all survivors regardless of age, type of cancer, or treatment location. Population Served ,, CEO Comments The Vanderbilt-Ingram Cancer Center is the organization without walls that unites all of the cancer-related activities of Vanderbilt University and Medical Center, including clinical care, research and education. The number of staff listed above represents a tiny fraction of our team -- in truth, the Center unites more than 300 faculty and more than 1,000 staff in cancer clinical units and departments in Vanderbilt Hospital and Clinic, the Monroe Carell Jr. Children’s Hospital at Vanderbilt, in Williamson and Montgomery counties, and in more than 100 research laboratories across the campus. Formed in 1993, the Center is one of an elite group of 45 National Cancer Institute Comprehensive Cancer Centers and a member of the National Comprehensive Cancer Network, a non-profit alliance of 21 leading centers working together to improve the quality of cancer care for patients everywhere. The Center provides multi-disciplinary care for all cancers, with special strength in clinical trials; colorectal, lung, breast, prostate, head/neck, kidney cancers; leukemias and lymphomas; and sarcomas. Our research focuses on translation -- linking discovery and delivery of care for the benefit of patients -- and in areas where we can have the greatest impact on death and suffering from cancer, including early detection and prevention and development of innovative, more personalized and targeted therapies. The Center is consistently listed among the best places for cancer care by U.S. News & World Report. 8 Governance Board Chair Board Chair Orrin Ingram Company Affiliation Ingram Industries Term Apr 2007 to Apr 2016 Board Members Name Affiliation Status Carolyn Aldige Cancer Research & Prevention Foundation Voting Helen Alexander Community Volunteer Voting Yvette Boyd Community Volunteer Voting Tommy Boyle Community Volunteer Voting James C. Bradford Community Volunteer Voting John F. Brock IV Community Volunteer Voting Dorothy Brotherton Community Volunteer Voting Andrew Byrd Andrew W. Byrd & Co. LLC Voting Doreatha Churchwell Community Volunteer Voting David Corlew Community Volunteer Voting Rebecca Brock Dixon Community Volunteer Voting Farzin Ferdowsi Community Volunteer Voting Beth Franklin Multi-Task Solutions, LLC Voting Mimi Gracida Community Volunteer Voting Janet Greene Community Volunteer Voting Donna Hall Community Volunteer Voting Dell Hancock Community Volunteer Voting Orrin Ingram Ingram Industries Voting Ronnie James Community Volunteer Voting Douglas H. Joyce Community Volunteer Voting Robert Lipman Community Volunteer Voting Tony Martell Sony Music Voting Kathy Mattea Musician Voting Albert Menefee III Menefee Equipment Co. Voting Carol O'Hare Community Volunteer Voting Cano Ozgener Community Volunteer Voting Clay Petrey Ayers Asset Mgmt. Inc. Voting James Congdon Seabury III Community Volunteer Voting Susan Simons Community Volunteer Voting Board Demographics - Ethnicity African American/Black 2 9 Asian American/Pacific Islander 0 Caucasian 27 Hispanic/Latino 0 Native American/American Indian 0 Other 0 Board Demographics - Gender Male 15 Female 14 Unspecified 0 Governance Board Term Lengths 3 Board Term Limits 2 Board Meeting Attendance % 70% Written Board Selection Criteria? No Written Conflict of Interest Policy? Under Development Percentage Making Monetary Contributions 86% Percentage Making In-Kind Contributions 86% Constituency Includes Client Representation No Number of Full Board Meetings Annually 2 Standing Committees Development / Fund Raising Community Outreach / Community Relations CEO Comments The Vanderbilt-Ingram Cancer Center is the umbrella organization that unites all of the cancer-related activities of Vanderbilt University and Medical Center, including clinical care, research and education. While the number of staff who have the Center as a “home department” is small, the Center unites more than 300 faculty and more than 1,000 staff in cancer clinical areas in Vanderbilt Hospital and Clinic, the Monroe Carell Jr. Children’s Hospital at Vanderbilt, in Williamson and Montgomery counties, and in more than 100 research laboratories across the campus. Formed in 1993, the Center is one of an elite group of 45 National Cancer Institute Comprehensive Cancer Centers and a member of the National Comprehensive Cancer Network, a non-profit alliance of 21 leading centers working together to improve the quality of cancer care for patients everywhere. 10 Management Executive Director/CEO Executive Director Jennifer A. Pietenpol Ph.D. Term Start Jan 2008 Email [email protected] Former CEOs Name Term Raymond DuBois M.D., Ph.D. 2005 - 2007 Harold Moses M.D. 1993 - 2004 Staff Full Time Staff 0 Part Time Staff 0 Volunteers 0 Contractors 0 Retention Rate 93% Plans & Policies Does the organization have a documented Fundraising Plan? Under Development Does the organization have an approved Strategic Plan? Yes In case of a change in leadership, is a Management Succession plan in place? Yes Does the organization have a Policies and Procedures Plan? Yes Does the organization have a Nondiscrimination Policy? Yes Does the organization have a Whistle Blower Policy? Yes Does the organization have a Document Destruction Policy? Yes Affiliations Affiliation Year Nashville Area Chamber of Commerce 2008 Williamson County Chamber of Commerce 2008 Bridges to Care - Safety Net Provider 2008 11 Community Shares 2008 Rural Health Association of Tennessee 2008 Tennessee Cooperative Cancer Coalition 2003 National Association of Social Workers 2008 Chamber of Commerce 2008 Association of American Medical Colleges 2008 Tennessee Hospital Association 2008 External Assessments and Accreditations Assessments/Accreditations Year Accreditation Council for Continuing Medical Education - Accreditation 2015 Centers for Medicare and Medicaid Services (U.S. Department of Health and Human Services) Medicare Certification 2015 Joint Commission on Accreditation of Healthcare Organizations (JCAHO) - Behavioral Health Care Accreditation 2015 Joint Commission on Accreditation of Healthcare Organizations (JCAHO) - Hospital Accreditation 2015 Awards Awards Award/Recognition Organization Year Specialized Programs of Research National Cancer Institute Excellence in Breast Cancer 2013 Designation/membership National Comprehensive Cancer Network 2015 Comprehensive Cancer Center Designation National Cancer Institute 2015 Best Cancer Hospitals US News & World Report 2015 Specialized Programs of Research National Cancer Institute Excellence in GI Cancer 2012 Senior Staff Scott Hiebert Ph.D. Title Associate Director for Basic Research and Shared Resources Experience/Biography Dan Beauchamp M.D. Title Deputy Director Experience/Biography 12 William Blot Ph.D. Title Associate Director for Population-Based Research Experience/Biography Lauren Hackett M.P.A. Title Executive Director for Administration and Chief Business Officer Experience/Biography Ann Richmond Ph.D. Title Associate Director for Research Education Experience/Biography Xiao-Ou Shu M.D., Ph.D., M.P.H. Title Associate Director for Global Health Experience/Biography Yu Shyr Ph.D. Title Associate Director for Quantitative Sciences Experience/Biography Carlos Arteaga M.D. Title Associate Director for Clinical Research Experience/Biography CEO Comments The Vanderbilt-Ingram Cancer Center is the umbrella organization that unites all of the cancer-related activities of Vanderbilt University and Medical Center, including clinical care, research and education. While the number of staff who have the Center as a “home department” is small, the Center unites more than 300 faculty and more than 1,000 staff in cancer clinical areas in Vanderbilt Hospital and Clinic, the Monroe Carell Jr. Children’s Hospital at Vanderbilt, in Williamson and Montgomery counties, and in more than 100 research laboratories across the campus. Formed in 1993, the Center is one of an elite group of National Cancer Institute Comprehensive Cancer Centers and a member of the National Comprehensive Cancer Network, a non-profit alliance of leading centers working together to improve the quality of cancer care for patients everywhere. 13 Financials Fiscal Year Fiscal Year Start July 01 2015 Fiscal Year End June 30 2016 Projected Revenue $0.00 Projected Expenses $0.00 Endowment Value $0.00 Endowment Spending Policy N/A Endowment Spending Percentage (if selected) 0% Detailed Financials Revenue and Expenses Fiscal Year Total Revenue Total Expenses Revenue Sources Fiscal Year Foundation and Corporation Contributions Government Contributions Federal State Local Unspecified Individual Contributions Indirect Public Support Earned Revenue Investment Income, Net of Losses Membership Dues Special Events Revenue In-Kind Other 2009 $33,879,544 $35,309,858 2008 $46,155,327 $38,660,178 2007 $39,299,933 $35,772,034 2009 $6,551,504 2008 $15,116,340 2007 $8,391,214 $18,178,853 $18,178,853 $0 $0 $0 $8,438,689 $0 $0 $142,480 $0 $0 $0 $568,018 $22,383,641 $22,383,641 $0 $0 $0 $6,284,547 $0 $0 $57,805 $0 $0 $0 $2,312,994 $20,913,883 $20,913,883 $0 $0 $0 $2,875,504 $0 $0 $432,933 $0 $0 $0 $6,686,399 14 Expense Allocation Fiscal Year Program Expense Administration Expense Fundraising Expense Payments to Affiliates Total Revenue/Total Expenses Program Expense/Total Expenses Fundraising Expense/Contributed Revenue Assets and Liabilities Fiscal Year Total Assets Current Assets Long-Term Liabilities Current Liabilities Total Net Assets Short Term Solvency Fiscal Year Current Ratio: Current Assets/Current Liabilities Long Term Solvency Fiscal Year Long-Term Liabilities/Total Assets Top Funding Sources Fiscal Year Top Funding Source & Dollar Amount Second Highest Funding Source & Dollar Amount Third Highest Funding Source & Dollar Amount 2009 $32,909,777 $2,400,081 $0 $0 0.96 93% 0% 2008 $37,296,779 $1,363,399 $0 $0 1.19 96% 0% 2007 $34,360,860 $1,411,174 $0 $0 1.10 96% 0% 2009 $0 $0 $0 $0 $0 2008 $0 $0 $0 $0 $0 2007 $0 $0 $0 $0 $0 2009 -- 2008 -- 2007 -- 2009 -- 2008 -- 2007 -- 2009 --- 2008 --- 2007 --- -- -- -- Capital Campaign Is the organization currently conducting a Capital Campaign for an endowment or the purchase of a major asset? No Capital Campaign Goal $0.00 Capital Campaign Anticipated in Next 5 Years? No State Charitable Solicitations Permit TN Charitable Solicitations Registration Exempt - Expires 0 Registration No 0 GivingMatters.com Financial Comments Financial figures for Ingram Cancer Center are taken from internal documents. Vanderbilt University submits one 990 and has one audit. The departments/programs are not isolated in the audit or 990. Vanderbilt Department of Finance reviewed documents provided by Ingram Cancer Center to GivingMatters.com. Assets are not included in GivingMatters.com as all assets belong to Vanderbilt. Fundraising expenses are accounted for in a different department and were not provided to GivingMatters.com. 15 Financial documents provided by KPMG. Comments provided by Amy McDaniel 08/2010. Created 04.30.2017. Copyright © 2017 The Community Foundation of Middle Tennessee 16